EA200901550A1 - Способы лечения, диагностирования и выявления ассоциированных с fgf21 нарушений - Google Patents

Способы лечения, диагностирования и выявления ассоциированных с fgf21 нарушений

Info

Publication number
EA200901550A1
EA200901550A1 EA200901550A EA200901550A EA200901550A1 EA 200901550 A1 EA200901550 A1 EA 200901550A1 EA 200901550 A EA200901550 A EA 200901550A EA 200901550 A EA200901550 A EA 200901550A EA 200901550 A1 EA200901550 A1 EA 200901550A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
fgf21
disturbances
diagnosis
treatment
Prior art date
Application number
EA200901550A
Other languages
English (en)
Inventor
Чэн Лиу
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA200901550A1 publication Critical patent/EA200901550A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Abstract

В заявке описаны, среди прочего, способы лечения рака и болезни сосудов, композиции, предназначенные для лечения рака и болезни сосудов, и способы и композиции, предназначенные для диагностирования и/или выявления рака и болезни сосудов.
EA200901550A 2007-05-22 2008-05-20 Способы лечения, диагностирования и выявления ассоциированных с fgf21 нарушений EA200901550A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93951207P 2007-05-22 2007-05-22
PCT/US2008/006481 WO2008153705A2 (en) 2007-05-22 2008-05-20 Methods of treating, diagnosing and detecting fgf21-associated disorders

Publications (1)

Publication Number Publication Date
EA200901550A1 true EA200901550A1 (ru) 2010-10-29

Family

ID=39739850

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200901550A EA200901550A1 (ru) 2007-05-22 2008-05-20 Способы лечения, диагностирования и выявления ассоциированных с fgf21 нарушений

Country Status (11)

Country Link
US (1) US20110002845A1 (ru)
EP (1) EP2152737A2 (ru)
JP (1) JP2010529954A (ru)
KR (1) KR20100017169A (ru)
CN (1) CN101679501A (ru)
AU (1) AU2008262450A1 (ru)
BR (1) BRPI0812384A2 (ru)
CA (1) CA2687746A1 (ru)
EA (1) EA200901550A1 (ru)
MX (1) MX2009012625A (ru)
WO (1) WO2008153705A2 (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
EA032727B1 (ru) 2008-10-10 2019-07-31 Амген Инк. Мутантный резистентный к протеолизу полипептид fgf21 и его применение
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
HRP20240135T1 (hr) 2009-05-05 2024-04-12 Amgen Inc. Fgf21 mutanti i njihove upotrebe
WO2010139741A1 (en) * 2009-06-04 2010-12-09 Novartis Ag Fgf-21 for treating cancers
WO2010148142A1 (en) 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
US8535912B2 (en) * 2009-10-15 2013-09-17 Genentech, Inc. Chimeric fibroblast growth factors with altered receptor specificity
JP2013512672A (ja) 2009-12-02 2013-04-18 アムジエン・インコーポレーテツド ヒトＦＧＦＲ１ｃ、ヒトβ−クロト−、ならびにヒトＦＧＦＲ１ｃおよびヒトβ−クロト−の両方に結合する結合タンパク質
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
RU2610661C2 (ru) * 2010-04-09 2017-02-14 Курна, Инк. Лечение заболеваний, связанных с фактором роста фибробластов 21 (fgf21), путем ингибирования природного антисмыслового транскрипта к fgf21
AU2011239689A1 (en) 2010-04-15 2012-11-08 Amgen Inc. Human FGF receptor and beta-Klotho binding proteins
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
US20120237975A1 (en) 2010-10-01 2012-09-20 Jason Schrum Engineered nucleic acids and methods of use thereof
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CN102296110B (zh) * 2011-07-18 2016-08-10 西北农林科技大学 一种检测黄牛fgf21基因单核苷酸多态性的方法
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2850624A1 (en) 2011-10-03 2013-04-11 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
CA2868398A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP6144355B2 (ja) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 化学修飾ｍＲＮＡ
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
SG11201701711VA (en) 2014-09-16 2017-04-27 Regeneron Pharma Anti-glucagon antibodies and uses thereof
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
CN107449715B (zh) * 2016-05-30 2021-01-22 康建胜 活细胞胞内代谢分析仪及其分析方法
EA201991203A1 (ru) 2016-11-17 2019-10-31 Способы лечения ожирения антителами к angptl8
WO2018144749A1 (en) * 2017-02-01 2018-08-09 Children's Medical Center Corporation Fgf21 compositions for treatment or prevention of neovascularization of the eye and methods therefor
WO2018187418A1 (en) * 2017-04-04 2018-10-11 Genentech, Inc. Substrates recognized by fibroblast activation protein (fap) and methods of using the same
JP7066540B2 (ja) * 2018-06-14 2022-05-13 株式会社日立製作所 デジタルｐｃｒの測定方法および測定装置
CN110279847B (zh) * 2019-05-17 2023-04-14 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 Fgf21在制备促进超长随意皮瓣存活的药物中的应用
CN110257512A (zh) * 2019-05-20 2019-09-20 上海交通大学医学院 用于luminal型和HER2型乳腺癌诊断、治疗及预后的标志物和组合物
CN111420030B (zh) * 2020-05-12 2021-01-29 江南大学 Fgf21在制备用于治疗结直肠癌药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7368100A (en) * 1999-09-10 2001-04-10 Curagen Corporation Fibroblast growth factor polypeptide and nucleic acids encoding same
US6716626B1 (en) * 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
WO2001038357A2 (en) * 1999-11-22 2001-05-31 Millennium Pharmaceuticals, Inc. Jaffa, a novel fibroblast growth factor family member and uses therefor
EP1666594A3 (en) * 2000-06-02 2006-06-21 Genentech, Inc. Polypeptide, nucleic acid encoding it, and their use for the diagnosis of cancer
WO2004022723A2 (en) * 2002-09-09 2004-03-18 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
JP2008522617A (ja) * 2004-12-14 2008-07-03 イーライ リリー アンド カンパニー 線維芽細胞成長因子２１の突然変異タンパク質
US20080261875A1 (en) * 2005-01-21 2008-10-23 Eli Lilly And Company Method For Treating Cardiovascular Disease
JP2006246823A (ja) * 2005-03-11 2006-09-21 Kyoto Univ 造血因子としてのＦｇｆ２１の使用

Also Published As

Publication number Publication date
MX2009012625A (es) 2009-12-07
JP2010529954A (ja) 2010-09-02
EP2152737A2 (en) 2010-02-17
CN101679501A (zh) 2010-03-24
KR20100017169A (ko) 2010-02-16
WO2008153705A3 (en) 2009-03-05
WO2008153705A2 (en) 2008-12-18
US20110002845A1 (en) 2011-01-06
CA2687746A1 (en) 2008-12-18
BRPI0812384A2 (pt) 2014-12-02
AU2008262450A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
EA200901550A1 (ru) Способы лечения, диагностирования и выявления ассоциированных с fgf21 нарушений
NO20084546L (no) Diagnostikk og behandlinger for tumorer
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
MX2007004176A (es) B7-h1 y metodos de diagnosis, prognosis, y tratamiento de cancer.
CY1119743T1 (el) Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1
EP4272757A3 (en) Modified nk-92 cells for treating cancer
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2008091692A3 (en) Methods of diagnosing, treating, and preventing increased vascular permeability
TW201129378A (en) Materials and methods for treating or preventing HER-3 associated diseases
BRPI0718850A2 (pt) Métodos de tratar, diagnosticar ou detectar câncer
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
WO2012054638A3 (en) Nmr systems and methods for the detection of analytes
BR112012002124A2 (pt) tratamento da doença de crohn com laquinimode.
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
MY160445A (en) Dual Variable Domain Immunoglobulins And Uses Thereof
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
EA201200793A1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
WO2010091049A3 (en) Diagnosis and treatment of cancer
BRPI0908635A8 (pt) composto, composição farmacêutica e método de tratamento de câncer
EA200970891A1 (ru) Генетические варианты chr2 и chr16 в качестве маркеров для применения при оценке риска, диагностировании, прогнозировании и лечении рака молочной железы
BRPI0813364A2 (pt) Métodos de diagnóstico e tratamento de câncer.
BR112015028338A2 (pt) métodos de diagnóstico ou de auxílio no diagnóstico e de tratamento da doença inflamatória intestinal
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
EA201201324A1 (ru) Профилактика колоректального и желудочно-кишечного рака